All News
Half the Experts are Wrong (2.17.2023)
Dr. Jack Cush reviews the news and tries to stump the expert panel this week on the podcast.
Read Article
Gingival Inflammation Parallels Saliva “Cytokine Score”
Researchers at NYU College of Dentistry have developed a single score to describe the level of cytokines in the saliva, and this score is linked with the severity of clinical gum inflammation, according to a study
Read Article
New Laboratory Insights for the ANA+ Consult
A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD).
Read Article
New Laboratory Insights for the ANA+ Consult
A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD).
https://t.co/Ub9pUHPRrV https://t.co/5q2yrNLD5e
Links:
Dr. John Cush RheumNow ( View Tweet)
While his talk didn’t focus on treatment, thoughtfulness regarding treatment for pain is important to our patients. Dr. Mease @RWCSmtg @RheumNow #RWCS23 https://t.co/f946SSeRWo
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Shenoi discusses a new bio markers in sJIA lung disease. #RWCS23 @RheumNow @RWCSmtg https://t.co/Nn3KjmGNfu
Dr. Rachel Tate uptoTate ( View Tweet)
How do you treat sJIA lung disease? Lots of steroids. Lung disease may stabilize but may not resolve. Dr. Shenoi @RWCSmtg #RWCS23 @RheumNow https://t.co/d5HiRy4Ud4
Dr. Rachel Tate uptoTate ( View Tweet)
MIS-c 2023 updated diagnostic criteria broken down by information type. Dr. Shenoi #RWCS23 @RheumNow @RWCSmtg https://t.co/U24sQiEF37
Dr. Rachel Tate uptoTate ( View Tweet)
Have you heard of nipocalimab? It prevents IgG-FcRn by binding to the FcRn IgG binding site. This is one to watch in our diseases (RA, Sjogren’s, SLE, myopathies.) Dr. Postolova #RWCS23 @RheumNow @RWCSmtg https://t.co/qMGA6IdtUE
Dr. Rachel Tate uptoTate ( View Tweet)
Sex differences in neutrophils could be an interesting approach to consider with our diseases. I personally had no idea my neutrophils may be different than a males. A very interesting thought by Dr. Postolova @RWCSmtg #RWCS23 @RheumNow https://t.co/mZsFaCBk7f
Dr. Rachel Tate uptoTate ( View Tweet)
“Remote patient monitoring should be here to stay.” Here are some important codes needed for your clinical practice. #RWCS23 @RheumNow @RWCSmtg @alvinwellsmd https://t.co/dj1CpU7ChY
Dr. Rachel Tate uptoTate ( View Tweet)
Drug Safety Differences w/ New Therapies in RA
Safety outcomes for targeted synthetic or b/ts DMARDs used to treat RA were studied using data from the ARTIS registry.
https://t.co/U96LiasMhW https://t.co/f2oCHs04Q3
Links:
Dr. John Cush RheumNow ( View Tweet)
Comparison of MIS-C dz in kids and adults>21 (MISC - A). By Dr Susan Shenoi @RWCSmtg #rwcs23 https://t.co/jvsMLARkCA
Dr. John Cush RheumNow ( View Tweet)
Case reports of anifrolumab use in 2 pts w/ chronic, scarring discoid lupus unresponsive to steriods, HCQ, immunosuppressants & CTX. Case 1 SLEDAI from 13 to 2 in 24 weeks & CLASI-A from 26 to 3 in 20wks. Cs 2 CLASI-A decr 24 to 5 after 1 infusion https://t.co/JE3PVyskm4
Links:
Dr. John Cush RheumNow ( View Tweet)
Older Lupus Patients Need Follow-Up After Hospital Discharge
Medicare beneficiaries 65 and older with lupus faced dramatically higher mortality when they received no follow-up care during the month after a hospital stay, researchers found.
https://t.co/4mFctXGQH9 https://t.co/2Q1z03myud
Links:
Dr. John Cush RheumNow ( View Tweet)
It's time to play, know your numbers! You know that famous game we play almost every other week, every other year.
https://t.co/JgCJzSuzHZ https://t.co/oiyB8vCOuD
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 232 pediatric #SLE pts. Over 12 mos 47% achieved LLDAS & Damage seen in 40% after 6.2 yrs F/U. Getting to LLDAS w/in 12 mos is assoc w less damage. LLDAS w/in 12 mos more likely in Absence of renal involvement. https://t.co/pGethJCw4e https://t.co/eYpVueIKbf
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheums: Treating #RA, Do you Consider/Use RA Rx guidelines?
Dr. John Cush RheumNow ( View Tweet)
On Dec. 19, 2022, the U.S. Food & Drug Administration (FDA) approved subcutaneous abaloparatide (Tymlos) for the treatment of men with osteoporosis at high risk of fracture https://t.co/igwxVCdKuo https://t.co/COSmDrsv4p
Links:
Dr. John Cush RheumNow ( View Tweet)
Alternatives to Vagal nerve stimulation Dr Eric Ruderman #RWCS23 @RWCSmtg https://t.co/zpJsh10LLQ
Dr. John Cush RheumNow ( View Tweet)